@adssx and @CronosTempi I appreciate the ongoing dialogue + findings discussions, as I’m one of those fighting early-onset PD. My current simplifying protocol is diet (Mediterranean/pescetarian/minimal dairy + red meat) and exercise (resistance and 80%+ heart rate cardio).
I take B-12 and fish oil omega-3 supplements too, plus rapa (hence being here!). I guess I’ll be measuring any success at a decadal level of resolution.
Sorry to hear that. You might be interested in my “strategy”: Parkinson's disease - #429 by adssx
I changed a bit my “stack”. It’s now (besides the usual sleep, diet, exercise, stress management, etc.):
Unchanged:
Added:
Testing:
Dropped:
Undecisive:
Interesting:
If you take B12 take methylcobalamin.
Omega-3: There’s 0 evidence in PD. Actually, there’s 0 evidence in any condition, with the exception of EPA (eicosapentaenoic acid) in those with high triglycerides.
All good stuff to check in on. Here’s my stack/recent history:
I have elevated homocystiene levels that have dropped slightly since starting peptides, but that seems speciously correlated. Any thoughts on methyl guard?
Evidence for all those vitamins seems very weak to me (in general for longevity and for PD in particular). That’s why I don’t take it. I take methylcobalamin (forgot it in my previous message, just edited it), but only because otherwise I’m borderline deficient.
Liraglutide/tirzepatide: Did you notice any benefit? Why liraglutide? In the phase 3 exenatide trial people on exenatide were slightly worse off than placebo. I think GLP1-RAs might work better on people with some glucose regulation issues. What was your HOMA-IR before starting GLP-1RAs?
I have decided (following test results) to take a cut down supplement stack on fasting days of b(5,6,7,9,12) and d3
A drug–microbiome–drug interaction impacts co-prescribed medications for Parkinson’s disease
https://www.nature.com/articles/s41564-026-02299-2
" Iron binding to COMT-I drugs modulates their antibacterial activity
Previous literature describes the iron chelating ability of catechols34,35, including nitrocatechols such as entacapone30. Similar to previous reports of other nitrocatechols35, incubation of tolcapone with either ferrous iron (Fe2+ in FeSO4; Fig. 2a) or ferric iron (Fe3+ in FeCl3; Fig. 2b) results in a red shift in ultraviolet–visible (UV–vis) light absorbance, consistent with iron binding. This shift does not occur when M1 or M2 is incubated with ferrous or ferric iron, suggesting a lack of iron binding by these metabolites (Extended Data Fig. 3a,b)."
How does this look when you throw in lactoferrin?
Combination Disease-Modifying Therapy for Neurodegenerative Diseases Using Repurposed Drugs 2026
That’s kind of my strategy as well with my combos… Is it working? God knows!
Apologies if this has been posted before…
https://x.com/Neuroscope_mp/status/2041486879929876484?s=20
clinical trial details: ClinicalTrials.gov
Video:
The discussion centers on the potential of smartphone applications in aiding the monitoring, diagnosis, and detection of Parkinson’s disease, particularly focusing on a keyboard typing application. The speaker highlights their involvement with a company that utilizes technology to track changes in typing behavior, which can serve as a sensitive indicator of disease progression and treatment response. This approach aims to complement existing diagnostic methods such as the FDA-approved SPECT-Ioflopane imaging study, commonly known as the virtual DaT scan, which evaluates the integrity of the nigrostriatal dopaminergic system.
https://www.neurologylive.com/view/use-of-smartphone-apps-for-pd-management
A drug known only as compound X helped to remove the problematic proteins associated with Parkinson’s disease from the brains of mice, and improved their balance and mobility
full story: Mysterious ‘compound X’ clears toxic Parkinson’s proteins from brain (New Scientist)
So sorry to hear about your Dx, Antoine. Knowing how detailed your research of the literature is (I appreciate these posts in particular), no doubt you’ll leave no stone unturned.
Article implies this is a repurposed compound. Any idea what the compound is? Supposedly it helps improve deep sleep and glymphatic drainage.
ChatGPT’s best guess:
Based on the reported effects, especially increased slow-wave sleep and glymphatic clearance, this is almost certainly a repurposed CNS-active sleep-modulating drug.
Top candidates:
Suvorexant
Lemborexant
Daridorexant
These fit best because orexin antagonists directly enhance deep sleep, which is strongly linked to glymphatic activity and protein clearance.
Secondary possibilities:
Trazodone
Gabapentin
Less likely, but still plausible due to effects on sleep architecture.
Bottom line: an orexin antagonist is the most likely class.
Google’s Gemini suggested Dexmedetomidine (brand name Precedex) is an FDA-approved drug (used in ICU for sedation and for Delirium management) that has been shown in studies to boost slow brain waves and enhance glymphatic drainage, possibly in combination with Midodrine. A March 2026 study found this combination (ACX-02) effectively clears amyloid and tau in humans compared to placebo: Pharmacological enhancement of glymphatic function in humans increases the clearance of Alzheimer’s disease-related proteins
My version of Google Gemini 3 Pro suggested these possible drugs as “compound X”:
The exact identity of “Compound X” remains proprietary while the Swinburne University team secures intellectual property rights. However, isolating the pharmacological clues in the provided text significantly narrows the field of possibilities.
Here is the functional profile of the mystery drug:
By cross-referencing these characteristics, three highly probable candidates emerge.
These modern insomnia medications are currently the strongest candidates for Compound X.
An older atypical antidepressant that is widely prescribed off-label as a sleep aid.
An FDA-approved anti-epileptic medication with a unique pharmacological profile.
Why it is likely not Sodium Oxybate (Xyrem): While sodium oxybate is the most famous FDA-approved drug for increasing slow-wave sleep (prescribed for narcolepsy), it is a highly water-soluble sodium salt. It dissolves readily in water or saline without the strict need for a methylcellulose suspension, making it a poor fit for the study’s formulation clue.
@tananth , I also asked Gemini 3 Pro if your paragraph/drug suggestion might be a candidate, and it replied as follows:
It is highly unlikely that Compound X is dexmedetomidine or the ACX-02 combination, despite the pharmacological similarities in their mechanism of action.
You are referencing the March 2026 clinical trial data published by Applied Cognition, which demonstrated that ACX-02 (intravenous dexmedetomidine combined with oral midodrine) successfully increased the clearance of amyloid beta and tau in humans by approximately 9–10%.
While dexmedetomidine is currently the gold standard for pharmacologically enhancing glymphatic transport via slow-wave sleep induction, it directly conflicts with three established facts regarding Swinburne University’s “Compound X”:
1. The Formulation and Solubility Mismatch
The Swinburne study explicitly noted that the control mice received methylcellulose, a suspending agent required to help Compound X dissolve. This indicates that Compound X is highly lipophilic and has poor aqueous solubility.
Dexmedetomidine hydrochloride is highly water-soluble. It is universally supplied as a clear, aqueous solution (in 0.9% sodium chloride) for intravenous or intraperitoneal injection. It does not require methylcellulose for murine dosing.
2. The Intellectual Property Landscape
Swinburne researcher Zhao Yan stated: “We aim to put some [intellectual property] protection around the repurposing of compound X…” ACX-02 is the proprietary lead candidate of the California-based biotech firm Applied Cognition, which has already filed a new chemical entity (NCE) patent application for this specific fixed-dose combination. Swinburne University would not be able to secure novel IP for repurposing dexmedetomidine to enhance glymphatic clearance, as the patent space for this exact mechanism is already occupied by Applied Cognition.
3. The Claim of Scientific Novelty
Yan explicitly stated that “no study has directly explored its effect on brain waste clearance before.” This completely eliminates dexmedetomidine. Dexmedetomidine has been the subject of intensive glymphatic research for over a decade. It was the primary anesthetic agent utilized by Maiken Nedergaard’s laboratory in the foundational murine studies that originally proved the existence and mechanics of the glymphatic system.
Conclusion
While the ACX-02 trial proves the therapeutic viability of boosting slow brainwaves to clear neurotoxic proteins, dexmedetomidine’s physical chemistry and extensive prior art rule it out as Swinburne’s mystery drug. Compound X must be a heavily lipophilic, previously untested oral agent—making Dual Orexin Receptor Antagonists (DORAs) like suvorexant or lemborexant the most statistically probable candidates.
And the free version of Claude.ai and its response:
Based on my research, I now have enough evidence to build a well-reasoned analysis. Here is a comprehensive breakdown of the candidate drugs and the evidence for each.
The text provides several key forensic clues to narrow down Compound X:
Here are the candidates, ranked by evidence strength:
Top Candidate: Sodium Oxybate (Xyrem / Xywav)What it is: Sodium oxybate is the gamma-hydroxybutyrate (GHB) salt, an endogenous metabolite of the inhibitory neurotransmitter GABA. It received FDA approval in 2002 for managing cataplexy or excessive daytime sleepiness in narcolepsy patients.
Why it fits — the slow-wave sleep link:
Sodium oxybate, also known as γ-hydroxybutyrate (GHB), is a sedative anesthetic compound known to increase slow-wave sleep and, to a lesser extent, REM sleep. It is arguably the most potent known pharmacological enhancer of slow-wave sleep in existence.
Why it fits — direct Parkinson’s disease testing:
A randomized, double-blind, placebo-controlled crossover trial in patients with Parkinson’s disease and excessive daytime sleepiness found that sodium oxybate substantially improved sleep, significantly enhancing objectively measured slow-wave sleep duration by an average of 72.7 minutes.
Why it fits — the alpha-synuclein mouse model connection:
Slow-wave sleep modulation in mouse models of Parkinson’s disease shows that sleep-modulating treatments enhancing slow waves in both VMAT2-deficient and A53T mouse models of PD reduced pathological αSyn accumulation compared to control animals. The enhancement of slow-wave sleep was associated with increased recruitment of aquaporin-4 to perivascular sites, suggesting a possible increase of glymphatic function. That 2021 study in Science Translational Medicine (Morawska et al.) was the first preclinical proof that sodium oxybate reduces alpha-synuclein, but importantly, it only suggested glymphatic improvement via AQP4 staining — it did not directly measure glymphatic fluid flow. Zhao Yan’s experiment appears to be exactly that next step.
Why it fits — the “repurposing” framing:
Sodium oxybate is primarily used to reduce excessive daytime sleepiness and cataplexy in narcolepsy. It also enhances slow-wave sleep and can reduce prefrontocortical alpha-synuclein neuropathology in aged PD model mice. Applying a narcolepsy drug as a disease-modifying Parkinson’s therapy is a classic drug repurposing context.
Why it fits — the glymphatic-but-never-directly connection:
The increase in slow-wave sleep with sodium oxybate could contribute to glymphatic function. However, these are only hypotheses thus far, highlighting potential directions for future studies. This matches Zhao Yan’s statement precisely: compound X “has been shown to boost slow brainwaves…but no study has directly explored its effect on brain waste clearance.”
Methylcellulose note: Sodium oxybate is typically formulated as an oral solution for human use, but in animal studies it is often administered by intraperitoneal injection or oral gavage. Methylcellulose in the vehicle formulation is consistent with rodent oral dosing studies.
Overall: The convergence of evidence is nearly exact. Sodium oxybate is the overwhelmingly strongest candidate.
Secondary Candidate: Dexmedetomidine (Precedex)What it is: Dexmedetomidine promotes glymphatic function through neural, inflammatory, and vascular pathways. NE levels decline during NREM sleep or under dexmedetomidine anesthesia, facilitating astrocyte relaxation, ECS expansion, and glymphatic flow, a state corresponding to slow-wave EEG activity.
Why it fits: Dexmedetomidine promotes biomimetic NREM stage 3 sleep in humans, and has been specifically proposed for repurposing as a glymphatic enhancer. A 2022 paper in Trends in Pharmacological Sciences was titled “Could dexmedetomidine be repurposed as a glymphatic enhancer?” — a perfect fit for the IP-protection/repurposing language Zhao Yan used.
Why it is less likely: Dexmedetomidine is primarily an intravenous/intramuscular sedative drug approved for ICU and procedural sedation contexts. Using it 4x/week in an ambulatory mouse model is operationally awkward (it would require injections), and it is far less established in Parkinson’s sleep literature than sodium oxybate. However, intranasal dexmedetomidine formulations do exist.
Tertiary Candidate: Dual Orexin Receptor Antagonists (Suvorexant/Lemborexant)What they are: Suvorexant is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin OX1 and OX2 receptors. It is approved for the treatment of insomnia by the FDA at doses of 5 to 20 mg.
Why they fit: Research has shown that during slow-wave sleep, glymphatic flux is heightened, increasing clearance of excess metabolites from the brain. Dual orexin receptor antagonists have been studied for their potential to mitigate sleep disturbances and enhance waste clearance in neurodegenerative diseases.
Why they are less likely: DORAs are newer sleep drugs (suvorexant approved 2014) and while they improve sleep architecture, they are weaker and less specific boosters of slow-wave activity compared to sodium oxybate. Their primary research context in neurodegeneration has been Alzheimer’s disease (amyloid clearance), not Parkinson’s/alpha-synuclein. Methylcellulose would be more appropriate for these poorly water-soluble compounds though.
| Feature | Sodium Oxybate | Dexmedetomidine | Suvorexant |
|---|---|---|---|
| FDA-approved |
 (2002) |
(1999) |
(2014) |
| Boosts slow brainwaves |
(strongest known) |
(NREM mimic) |
(modest) |
| Parkinson’s clinical data |
(multiple trials) |
 (limited) |
|
| Alpha-syn mouse model data |
(Morawska 2021) |
|
|
| Glymphatic link postulated |
(explicit) |
(explicit) |
(indirect) |
| “Repurposing” framing |
(narcolepsy → PD) |
(ICU → PD) |
(insomnia → PD) |
| Methylcellulose compatible | |
(injectable) |
(insoluble) |
Sodium oxybate (Xyrem/Xywav) is by far the most likely identity of Compound X. The 2021 study in Science Translational Medicine demonstrated that the narcolepsy drug sodium oxybate deepened slow waves in snoozing mice, and well-rested mice had more fluid-shuttling aquaporin-4 in their perivascular spaces — but the glymphatic interpretation remained indirect. Zhao Yan’s Swinburne study with the nasal alpha-synuclein model appears to be the first experiment to close that gap by directly measuring glymphatic fluid flow and waste clearance in a Parkinson’s context — exactly what the IP-protection language around “first disease-modifying treatment” and “no study has directly explored its effect on brain waste clearance” implies. All the pieces fit.
Unfortunately, we don’t know if the “problematic proteins associated with Parkinson’s disease” are really problematic and if the “brains of mice” are representative. Dozens of similar “compound X” before ended up failing.
Thanks @whladik, I’m trying my best 
By the way, it would be good to have more people with PD doing biohacking. I think biohacking and self-experimentation might yield more information and breakthroughs than trials (which have failed for the past century). Especially given the heterogeneity of this disease.
